Tocagen (NASDAQ:TOCA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Zacks.com reports. The firm currently has a $0.75 target price on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 27.12% from the company’s current price.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
Several other equities analysts also recently weighed in on the company. Robert W. Baird downgraded Tocagen from an “outperform” rating to a “neutral” rating in a research report on Thursday, September 12th. Chardan Capital reiterated a “hold” rating and set a $1.00 target price on shares of Tocagen in a research report on Wednesday. Citigroup downgraded Tocagen from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $20.00 to $1.00 in a research report on Friday, September 13th. HC Wainwright restated a “hold” rating on shares of Tocagen in a research report on Thursday. Finally, LADENBURG THALM/SH SH downgraded Tocagen from a “buy” rating to a “neutral” rating in a research report on Thursday, September 12th. Nine analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $10.23.
Shares of Tocagen stock traded down $0.01 on Friday, reaching $0.59. The company’s stock had a trading volume of 130,900 shares, compared to its average volume of 279,559. The company has a market capitalization of $14.78 million, a price-to-earnings ratio of -0.24 and a beta of 3.89. The company has a quick ratio of 4.21, a current ratio of 1.43 and a debt-to-equity ratio of 0.46. The firm’s fifty day simple moving average is $0.63 and its two-hundred day simple moving average is $4.23. Tocagen has a 52 week low of $0.53 and a 52 week high of $14.75.
Tocagen (NASDAQ:TOCA) last released its earnings results on Tuesday, November 12th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Tocagen had a negative net margin of 201,488.91% and a negative return on equity of 182.15%. As a group, research analysts predict that Tocagen will post -2.6 EPS for the current year.
Several institutional investors have recently made changes to their positions in TOCA. Acadian Asset Management LLC lifted its position in shares of Tocagen by 151.0% in the second quarter. Acadian Asset Management LLC now owns 92,450 shares of the company’s stock worth $618,000 after buying an additional 55,621 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Tocagen by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 476,684 shares of the company’s stock worth $3,074,000 after buying an additional 23,293 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Tocagen in the second quarter worth about $551,000. Dowling & Yahnke LLC lifted its position in shares of Tocagen by 41.2% in the second quarter. Dowling & Yahnke LLC now owns 17,122 shares of the company’s stock worth $114,000 after buying an additional 5,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Tocagen by 8.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 50,940 shares of the company’s stock worth $341,000 after buying an additional 3,767 shares in the last quarter. Institutional investors and hedge funds own 35.20% of the company’s stock.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Article: Market Indexes
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.